LOGIN  |  REGISTER
Cue Biopharma
Compass Therapeutics

Movano Health to Launch the Evie Ring on November 20

October 30, 2023 | Last Trade: US$3.21 2.10 188.20
  • The Company will begin taking orders for the smart ring designed for women's health through its commercial site www.eviering.com in time for Black Friday

PLEASANTON, Calif., Oct. 30, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the Evie Ring, today announced its launch plans for the Evie Ring, the smart ring designed for women's health.

Beginning on November 20, customers will be able to place an order for the Evie Ring exclusively through www.eviering.com for a retail price of $269 and no subscription fee. The ring will be available in sizes 5 – 12 and customers may elect to receive a complimentary sizing kit with their purchase.

The Evie Ring provides trusted health information for every woman at every stage. The ring measures health and wellness metrics including heart rate, blood oxygen saturation, sleep stages, activity levels, and menstrual cycles. The unique app experience is personalized to the user based on their specific health goals and provides healthy ranges rather than scoring activity or fitness performance. It also shares custom insights that draw data-based connections between how someone is feeling and their health data. The smart ring is designed to be flexible and accommodate swelling without compromising on style.

Movano Health has continued to make significant progress in its commercialization efforts that underscores its readiness to deliver a compelling product, including:

  • The Evie Ring and App are testing well, effectively analyzing data and delivering clear and actionable insights.
  • The Company's manufacturing partner is fully online and production processes are in place to ensure scalability.
  • A new commercial website at www.eviering.com will go live on November 20.
  • Movano Health is working closely with the FDA to navigate the regulatory process for medical device clearances following its first 510(k) submission earlier this year.
  • The Company began another round of testing the Evie Ring in October with a major health insurer and a leading remote patient monitoring company.
  • Movano Health is preparing to exhibit and showcase the Evie Ring at CES 2024.

For more information on the Evie Ring, visit www.eviering.com

About Movano Health

Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health's devices capture a comprehensive picture of a person's vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives. Movano Health's end-to-end solutions will soon enable consumers and their healthcare professionals to utilize daily medical-grade data as a tool to proactively monitor and manage health outcomes. For more information on Movano Health, visit https://movanohealth.com/

Forward Looking Statements

This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to commercial launch of the Evie Ring, anticipated FDA clearance for the Evie Ring, expected future operating results; product development and features, product releases, clinical trial, and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB